Website maintenance took place on Thursday 30 April 2026. If you experience any issues, please contact us.
Notice for alpelisib (Novartis Pharmaceuticals Australia Pty Ltd)
Active ingredients
alpelisib
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
tablet; granules
Indication
PIK3CA-related overgrowth syndrome (PROS)
Therapeutic area
Genetic disorder causing excessive growth of affected tissues